Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2014

View Archived Issues

Eli Lilly and Immunocore to discover and develop novel cancer therapies

TTP-054 demonstrates the ability to lower HbA1c in patients with type 2 diabetes

Chase Pharmaceuticals to begin phase II study of CPC-201

Researchers present novel ASOs as potential therapies for tauopathies

Virobay completes series B financing round

Enrollment completed in study of protein-based biomarker blood test for breast cancer

Novel agents for tuberculosis patented by Janssen R&D Ireland

Galapagos designs new GPR84 agonists

Cellerant Therapeutics divulges new anti-IL1RAP MAbs

AVEO Pharmaceuticals presents new anti-GDF-15 MAbs

Researchers at Rockefeller University patent new modified anti-CD4 MAbs

Significant benefits seen with DA-1229 in diabetes trial

New anti-Notch 3 antibodies selected by AVEO Pharmaceuticals

French group patents new spiroisoxazoline derivatives

Phase III trial of biosimilar of etanercept begins in chronic plaque psoriasis

Capricor Therapeutics reports results from phase I portion of the ALLSTAR trial

Isis Pharmaceuticals begins phase II study of ISIS-APO(a)Rx in patients with high Lp(a)

ImQuest Pharmaceuticals receives FDA approval to initiate trials of IQP-0528 gel

Resolve Therapeutics begins phase II study of RSLV-132 in SLE

OncoMed Pharmaceuticals begins phase II ALPINE trial of tarextumab

Phase III study of trametinib and dabrafenib in melanoma stopped early due to benefit

FDA grants breakthrough therapy designation to pirfenidone for IPF

Cynapsus begins phase II studies of APL-130277 in Parkinson's disease

Ruthigen treats first subjects in trial of RUT-58-60

Seres Health completes enrollment in study of SER-109

Researchers develop low-cost, rapid, point-of-care test for the detection of M. tuberculosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...